Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Appeals court upholds dismissal of Biogen Idec suit

This article was originally published in Scrip

Executive Summary

A US appeals court has upheld the dismissal of a consolidated class action brought by pension and annuity funds against Biogen Idec for the 2005 stock drop after the company temporarily withdrew its multiple sclerosis product Tysabri (natalizumab) from the market. A three-judge panel of the US Court of Appeals for the First Circuit denied the plaintiffs' appeal. The shares lost around 90% of their value in the aftermath of the withdrawal; the product was successfully returned to the market.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts